Gomekli™ (mirdametinib) – New orphan drug approval
February 11, 2025 - SpringWorks Therapeutics announced the FDA approval of Gomekli (mirdametinib), for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
Top